Business
Moderna Tumbles After Nonpartisan Pledge, First Sell Rating – Bloomberg
Moderna Inc. fell 13% on Tuesday after regulators and top drugmakers promised the Covid-19 vaccine approval process would be immune from political pressure and the biotech company drew its first sell rating since going public in 2018.
Moderna Inc. fell 13% on Tuesday after regulators and top drugmakers promised the Covid-19 vaccine approval process would be immune from political pressure and the biotech company drew its first sell rating since going public in 2018.
Moderna’s vaccine is one of three leading candidates Wall Street expects may win an emergency use authorization near-term.. But pledges from the Food and Drug Administration and industry leaders have cast a pall over the prospects of a vaccine being approved befor…
-
General22 hours agoDonald Trump’s initial 10 per cent tariff takes effect
-
General21 hours agoJaguar Land Rover in UK pauses shipments to US
-
General19 hours agoTexas opens probe into Kellogg’s health claims, dyes
-
General18 hours agoAustralian share market set to dive as threat of US recession grows